Evaluate Ltd Releases MedTech World Preview Report

September 26, 2017
Pharmaceutical Executive

Evaluate Ltd, a life science commercial intelligence firm, released a report revealing that Medtronic was the leading medtech company in 2016-with sales of nearly $30 billion-and will likely retain the crown in 2022 with sales predicted to reach $37.7 billion. Abbott jumped to third place with its acquisition of St. Jude.

Analysis highlights from the report include:

·       Total value of medtech M&A deals rises by a massive 178% in H1 2017

·       In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022

·       Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%

·       Total value of medtech IPOs continues to fall in H1 2017 to $122m

·       Global medtech R&D spend set to grow by 3.7% (CAGR) to $33.5bn by 2022

·       Following the 10 year high in 2015, number of first-time PMAs and HDEs down 22% in 2016

Full report: EvaluateMedTech World Preview 2017, Outlook to 2022